June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Metformin Protects Retinal Vascular Endothelial Cell Barrier Function from TNFα-induced Hyperpermeability in vitro and in vivo
Author Affiliations & Notes
  • Xiaoxi Qiao
    Ophthalmology, Henry Ford Health System, Detroit, MI
  • Jing Han
    Ophthalmology, Henry Ford Health System, Detroit, MI
    Ophthalmology, Tangdu Hospital, Xi'an, China
  • Xiuli Liu
    Ophthalmology, Henry Ford Health System, Detroit, MI
  • Tongrong Zhou
    Ophthalmology, Henry Ford Health System, Detroit, MI
  • Paul A Edwards
    Ophthalmology, Henry Ford Health System, Detroit, MI
  • Hua Gao
    Ophthalmology, Henry Ford Health System, Detroit, MI
  • Footnotes
    Commercial Relationships Xiaoxi Qiao, None; Jing Han, None; Xiuli Liu, None; Tongrong Zhou, None; Paul Edwards, None; Hua Gao, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2302. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xiaoxi Qiao, Jing Han, Xiuli Liu, Tongrong Zhou, Paul A Edwards, Hua Gao; Metformin Protects Retinal Vascular Endothelial Cell Barrier Function from TNFα-induced Hyperpermeability in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2302.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: We have previously reported that metformin, an anti-diabetic drug, has anti-angiogenic and anti-inflammatory effects directly on human retinal vascular endothelial cells (hRVECs). This study investigates if metformin also protects retinal vascular permeability from inflammatory insult induced by tumor necrosis factor-α (TNFα) in vitro and in vivo.

Methods: Primary hRVECs were grown in transwell to form monolayer and then challenged with TNFα with or without metformin treatment. Transwell permeability to FITC-dextran was assayed. The integrity of endothelial cell adhesion was determined by immunofluorescent staining of VE-cadherin and occludin. C57BL/6 mice with 50 ng intravitreal TNFα injection were treated with daily oral metformin or BSS vehicle 3 days before TNFα challenge for 10 days. Retinal vascular permeability was examined by quantifying albumin extravasation into the retinal parenchyma.

Results: TNFα at 2.5 and 5.0 ng/ml induced a dose-dependent increase of hRVEC monolayer permeability to FITC-dextran. Metformin 5 mM pretreatment completely blocked 2.5 ng/ml TNFα effect and significantly attenuate 5.0 ng/ml TNFα effect (p < 0.05). Immunofluorescent staining of VE-cadherin and occludin revealed that metformin pretreatment dose-dependently prevented TNFα-induced disruptions of hRVEC monolayer integrity. In vivo study showed that TNFα intravitreal injection led to a 3-fold remarkable increase of retinal albumin level, indicating a severe breakdown of blood-retinal barrier. In contrast, metformin treated animals had a normal retinal albumin level in the BSS injected control group (n = 5, p < 0.05).

Conclusions: These in vitro and in vivo results demonstrate that metformin protects the integrity of the retinal vascular endothelial cell barrier function from TNFα-induced inflammatory insult. It indicates that metformin may provide additional benefit to control retinal vascular hyperpermeability in the conditions such as diabetic retinopathy and other inflammatory retinal diseases.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×